Laying the Foundations for Long-Term Remission in High-Risk* Acute Myeloid Leukaemia (AML)
Dr Donal McLornan presents a case study in the context of the 5-year data for Vyxeos Liposomal.1
Prescribing information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.
Topics: Safety Vyxeos Liposomal Data